Justification Approval - Made in America Initiative - Morphine Solution Redaction Update.pdf

PDF 228 KB Posted

Attached to
Morphine Sulfate Solution
Solicitation number
SPE2D2-26-R-0017
Issued by

About this file

This document is a Justification for Other Than Full and Open Competition (OFTOC) under 10 U.S.C. § 3204(a)(3) for a morphine sulfate solution procurement by the Defense Logistics Agency (DLA) Troop Support, Medical Supply Chain.

The contracting activity seeks to award a single, five-year requirements contract on a lowest price technically acceptable (LPTA) basis, comprising one base year and four one-year option periods, with an estimated total value of $32,311,688.10. The morphine sulfate solution will serve the Department of War (DoW), Indian Health Service (IHS), Bureau of Prisons (BoP), and Department of Veterans Affairs (VA) through the DLA and VA Medical Prime Vendor Programs. Annual requirements include approximately 229,375 total units across nine product variations, including injections and intravenous solutions in concentrations ranging from 2 mg/mL to 10 mg/mL in syringes and vials. Competition is restricted to domestic sources where both the Active Pharmaceutical Ingredient (API) and Final Dosage Form (FDF) are manufactured domestically. The justification cites national defense preparedness, industrial mobilization goals, and supply chain resilience as reasons for the domestic-only restriction, aligned with Executive Order 14005 and OMB policy on strengthening domestic sourcing. Market research identified ten primary manufacturers and ten additional potential vendors, with three vendors expressing written interest: Fresenius Kabi LLC, Hikma Pharmaceuticals USA Inc., and Golden State Medical Supply Inc. The solicitation will be posted to SAM.gov with a presolicitation notice, and the Contracting Officer will verify fair and reasonable pricing using historical data from DLA, GSA, and VA schedules.

View the file

Other files

On GovTribe

Work with this file

  • Download the original file
  • Contacts named in this file
  • Similar government files
  • Ask GovTribe AI about this file

Text version

JUSTIFICATION FOR OTHER THAN FULL AND OPEN COMPETITION

UNDER AUTHORITY OF 10 U.S.C. 3204(a)(3)

MORPHINE SULFATE SOLUTION

1. Defense Logistics Agency (DLA) Troop Support, Medical Supply Chain, is the contracting activity.

2. The action being approved is the ability to solicit DLA requirements on an other than full and open competition basis. Competition will be restricted to domestic sources (vendors providing Active Pharmaceutical Ingredients (API) and Final Dosage Forms (FDF) manufactured domestically), the procurement will be competed among all qualified domestic manufacturers.

The purpose of this initiative is to award a national contract, in accordance with FAR 52.216-21 Requirements to provide morphine solution for purchase by Department of War (DoW), Indian Health Service (IHS), Bureau of Prisons (BoP) and the Department of Veterans Affairs (VA) customers through the Defense Logistics Agency (DLA) and VA Medical Prime Vendor Programs (PPV). This acquisition is expected to result in a single award, requirements contract awarded on a lowest price technically acceptable (LPTA) basis. The total contract length of the award will be for five (5) years encompassing a one (1) year base period and four (4) one (1) year option periods.

3. Following are the supplies required to meet DLA’s needs:

Item Description: Morphine Sulfate solution is used for the management of moderate to severe acute and chronic pain where an opioid analgesic is appropriate. Quantities below include utilization from the DoW, IHS, BoP, and the VA in individual units.

Quantity:

MORPHINE 2 MG/ML INJECTION SYRINGE – 71,329 per year MORPHINE 4 MG/ML INJECTION SYRINGE – 29,149 per year MORPHINE 10 MG/ML INJECTION SOLUTION VIAL – 2,616 per year MORPHINE 2 MG/ML INJECTION SOLUTION VIAL – 47,297 per year MORPHINE 10 MG/ML INTRAVENOUS SOLUTION VIAL – 12,652 per year MORPHINE 2 MG/ML INTRAVENOUS SYRINGE – 6,491 per year MORPHINE 10 MG/ML INTRAVENOUS SYRINGE – 376 per year MORPHINE 4 MG/ML INTRAVENOUS SOLUTION VIAL – 50,837 per year MORPHINE 4 MG/ML INJECTION SOLUTION VIAL – 8,628 per year

Number of Options: Four (4)

Estimated Dollar Value, inclusive of options: $32,311,688.10

4. The applicable statutory authority permitting other than full and open competition is 10 U.S.C.

§ 3204(a)(3) as implemented by Class Deviation 2026-O0017 Revision 2 – Revolutionary Federal Acquisition Regulation (FAR) Overhaul Part 6, Defense FAR Supplement (DFARS) Part 206, and Revolutionary FAR Overhaul Part 6.103-3Industrial mobilization; engineering, CUI

Source Selection Information-FAR 2.101 and 3.104

Controlled by: DLA Troop Support Controlled by: FSBC- National Contracts CUI Category: Source Selection Distribution/Dissemination Control: FED ONLY POC: jason.wray@dla.mil (445) 737-6304 mailto:jason.wray@dla.mil

MORPHINE SULFATE SOLUTION

CUI

Source Selection Information-FAR 2.101 and 3.104 developmental, or research capability; or expert services. This acquisition is also aligned with and in support of OMB policy issued March 13, 2024 “Strengthening Domestic Sourcing for Critical Items”.

5. The ongoing national security challenge of foreign-source dependency on life-saving pharmaceuticals poses an immediate, unacceptable risk to military readiness and civilian resilience during a national emergency. Section 8 of Executive Order (E.O.) 14005, Ensuring the Future is Made in All of America by All of America's Workers, directs government wide efforts to strengthen and modernize the implementation of the Buy American Act (BAA), 41 U.S.C. §§ 8301–8305. The principles outlined in E.O. 14005 encourage federal agencies to prioritize domestic production when feasible. Aligning this procurement with these priorities supports broader federal objectives to expand domestic manufacturing capacity, enhance supply chain resilience, and reinforce the U.S. industrial base. Strengthening domestic production of morphine solution will also better posture DoW to maintain uninterrupted access to critical pharmaceuticals in the event of future pandemics or geopolitical conflicts, including large scale war, where global supply chains may be severely disrupted.

• National Defense Preparedness: Limiting this solicitation to domestic producers ensures that critical manufacturing facilities, production lines, tooling, raw materials, and skilled labor pools remain viable within the United States. In the event of a global pandemic, geopolitical conflict, or supply chain embargo, reliance on foreign manufacturers (particularly in near-peer adversary countries) threatens the DoW's ability to treat casualties and maintain force health protection.

• Industrial Mobilization Goals: The Made in America (MiA) Office, Executive Office of the President and the Office of the Secretary of War have determined that relying on foreign suppliers creates dangerous vulnerabilities that can be exploited by actors hostile to U.S. interests during national emergencies. The MiA Office states that guaranteed federal procurement acts as a baseline buyer, reducing the financial risks of building or expanding production capability onshore. By utilizing a Requirements contract focused exclusively on domestic production, DLA and VA support the Administration’s domestic production expansion strategy by guaranteeing a steady baseline demand for domestic manufacturers. This critical joint five-year demand signal incentivizes the repatriation of active pharmaceutical ingredient (API) manufacturing to the United States, keeping active production lines "warm" and capable of rapid surge capacity. DLA’s experience and communications with its commercial partners indicate that other types of government contracts offering indefinite commitments provide less incentive to make the types of investments the Administration seeks to improve the nation’s production capacity.

• Ensuring Logistics Redundancy: Restricting competition to domestic sources under

FAR 6.103-3 is the only regulatory mechanism that allows DLA to actively exclude foreign-sourced items when there is an overwhelming national defense interest to build and preserve a reliable, domestic, industrial-mobilization base of pharmaceutical

MORPHINE SULFATE SOLUTION

manufacturers. Morphine solution is also currently available on the VA Federal Supply Schedule (FSS) from foreign manufacturers adhering to the Trade Agreements Act

(TAA).

6. Market Research Surveys have been sent to all FDA approved manufacturers and known pharmaceutical distributors to ascertain the feasibility of procuring domestically sourced Morphine Sulfate. Morphine Sulfate is a Commercial Off -The-Shelf (COTS) item. DLA will be seeking an item where the Active Pharmaceutical Ingredient (API) and Final Dosage Form (FDF) are both manufactured domestically. While RFO 25.105 Critical Components and Critical Items does not yet provide a list of critical items, Executive Order 14017 “America’s Supply Chains” directed agencies to conduct a 100-day assessment of America’s supply chains. The U.S. Department of Health and Human Services (HHS) produced a white paper titled “Policy Considerations to Prevent Drug Shortages and Mitigate Supply Chain Vulnerabilities in the United States”. In this paper Analgesics/Anesthetics such as morphine are identified as compromising seventeen percent (17%) of critical drug shortages. Morphine was identified by the Made in America Office as a drug with domestic API and FDF manufacturing, and the Defense Health Agency has prioritized morphine as a candidate for this initiative.

• Synopsis: Presolicitation Notice will be publicized on the Government-wide Point of Entry (SAM.gov) in accordance with FAR 5.101. The notice will clearly define the scope of the restriction to domestic producers.

• Competitive Sourcing: While competition is restricted to domestic sources (vendors providing API and FDF manufactured domestically), the procurement will be competed among all qualified domestic manufacturers to the maximum extent practicable. The DLA Troop Support Medical Directorate will leverage its existing network of domestic industrial partners and engage industry groups to encourage robust participation among domestic vendors. In accordance with FAR 5.201 the solicitation will be posted to SAM.gov.

7. The Contracting Officer will determine that the anticipated cost/price for the medical supplies and equipment is fair and reasonable prior to contract award. The Government will utilize historical price data from previous DLA medical contracts, General Service Administration (GSA) and Veteran’s Administration (VA) schedules, and current commercial market indices to evaluate proposed pricing.

8. Market research for this acquisition was conducted to determine the availability of Morphine Sulfate sources capable of providing the projected annual demand. Market research indicated there are ten (10) manufacturing companies providing Morphine Sulfate Solution in the commercial marketplace:

Fresenius Kabi USA LLC, Hikma Pharmaceuticals USA Inc., Hospira Inc., International medication Systems Ltd., Pharmaceutical Associates Inc., Piramal Critical Care Inc., Quagen Pharmaceuticals LLC, SpecGx LLC, Tris Pharma Inc., and Winder Laboratories LLC.

MORPHINE SULFATE SOLUTION

There were ten (10) other contractors currently providing Morphine Sulfate Solution or potentially interested in providing to DoD, VA, IHS and BoP through the VA FSS or DAPA:

AvKARE LLC, Exelan Pharmaceuticals Inc, Golden State Medical Supply, Inc, The Harvard Drug Group, Precision Dose, Inc., Civica Inc., Amphastar Pharmaceuticals, Inc., Teva Pharmaceuticals, Pfizer, Inc., and XLCare Pharmaceuticals Inc.

Although there were twenty (20) businesses identified, four (4) businesses had no record in Sam.gov. Market research surveys were then sent to sixteen (16) businesses (six (6) manufacturers and ten (10) other businesses currently providing Morphine Sulfate Solution). The surveys were sent to FDA approved companies, which can be found in Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm), and any vendors that have expressed interest in National Contracts.

9. Recent supply chain bottlenecks, export bans by foreign governments during health crises, and shipping container shortages highlight the danger of offshoring the production of basic medical necessities.

This action directly aligns with national initiatives and Executive Orders aimed at strengthening America's supply chains and ensuring critical materials (including public health and defense industrial base assets) are manufactured domestically.

10. The following is a list of vendors who responded in writing with interest to offer a proposal for Morphine Sulfate solution with domestic API and FDF:

• Fresenius Kabi, LLC

• Hikma Pharmaceuticals USA Inc.

• Golden State Medical Supply Inc.

11. DLA Troop Support is committed to fostering competition. To mitigate barriers to future competition, the agency will:

• Continuously monitor the domestic medical marketplace to identify emerging manufacturers, packaging facilities, and distributors.

• Coordinate with domestic industrial base expansion programs to lower entry barriers for new domestic startups seeking to enter the federal contracting arena.

• Periodically reassess the global and domestic supply landscape to determine if market conditions permit returning to full and open competition without compromising national security or mobilization readiness.

12. As the contracting officer, I hereby certify that this justification is accurate and complete to the best of my knowledge and belief.

https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm)

MORPHINE SULFATE SOLUTION

WRAY.JASON.CHR Digitally signed by

9/17/26

ISTOPHER.123874

WRAY.JASON.CHRISTOPHER.1

238740742 Date: 2026.09.17 14:15:32 -04'00'

DATE Jason Wray Contracting Officer

I hereby certify that the requirements which form the basis of this justification are accurate, that these supplies meet the Government’s needs in accordance with applicable specifications and that this justification is accurate and complete to the best of my knowledge and belief.

Digitally signed by

QUIGLEY.PATRICK.M.12395198

9/18/26 K.M.1239519802 02 Date: 2026.09.18 07:11:41 -04'00'

DATE Patrick Quigley Division Chief

I have reviewed and hereby approve this justification.

9/18/26

DATE MACIEJ OKULICZ-KOZARYN

DLA Troop Support Competition Advocate

OKULICZ

KOZARYN.MACIEJ. KOZARYN.MACIEJ.1248273654

1248273654

QUIGLEY.PATRIC

JUSTIFICATION FOR OTHER THAN FULL AND OPEN COMPETITION UNDER AUTHORITY OF 10 U.S.C. 3204(a)(3)

File details come from the government source that posted it. Updated .